Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2006

Open Access 01-12-2006 | Research

Better quality of life with neuropsychological improvement on HAART

Authors: Thomas D Parsons, Alyssa J Braaten, Colin D Hall, Kevin R Robertson

Published in: Health and Quality of Life Outcomes | Issue 1/2006

Login to get access

Abstract

Background

Successful highly active antiretroviral therapy (HAART) regimens have resulted in substantial improvements in the systemic health of HIV infected persons and increased survival times. Despite increased systemic health, the prevalence of minor HIV-associated cognitive impairment appears to be rising with increased longevity, and it remains to be seen what functional outcomes will result from these improvements. Cognitive impairment can dramatically impact functional ability and day-to-day productivity. We assessed the relationship of quality of life (QOL) and neuropsychological functioning with successful HAART treatment.

Methods

In a prospective longitudinal study, subjects were evaluated before instituting HAART (naïve) or before changing HAART regimens because current therapy failed to maintain suppression of plasma viral load (treatment failure). Subjects underwent detailed neuropsychological and neurological examinations, as well as psychological evaluation sensitive to possible confounds. Re-evaluation was performed six months after institution of the new HAART regimen and/or if plasma viral load indicated treatment failure. At each evaluation, subjects underwent ultrasensitive HIV RNA quantitative evaluation in both plasma and cerebrospinal fluid.

Results

HAART successes performed better than failures on measures exploring speed of mental processing (p < .02). HAART failure was significantly associated with increased self-reports of physical health complaints (p < .01) and substance abuse (p < .01). An interesting trend emerged, in which HAART failures endorsed greater levels of psychological and cognitive complaints (p = .06). Analysis between neuropsychological measures and QOL scores revealed significant correlation between QOL Total and processing speed (p < .05), as well as flexibility (p < .05).

Conclusion

Our study investigated the relationship between HIV-associated neurocognitive impairment and quality of life. HAART failures experienced slower psychomotor processing, and had increased self-reports of physical health complaints and substance abuse. Contrariwise, HAART successes experienced improved mental processing, demonstrating the impact of successful treatment on functioning. With increasing life expectancy for those who are HIV seropositive, it is important to measure cognitive functioning in relation to the actual QOL these individuals report. The study results have implications for the optimal management of HIV-infected persons. Specific support or intervention may be beneficial for those who have failed HAART in order to decrease substance abuse and increase overall physical health.
Literature
1.
Saykin AJ, Janssen RS, Sprehn GC, Kaplan JE, Spira TJ, O'Connor B: Longitudinal evaluation of neuropsychological function in homosexual men with HIV infection: 18-month follow-up. J Neuropsychiatry Clin Neurosci 1991,3(3):286–298.PubMedCrossRef
2.
Dunbar N, Perdices M, Grunseit A, Cooper DA: Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS. Aids 1992,6(7):691–700.PubMedCrossRef
3.
Selnes OA, Galai N, Bacellar H, Miller EN, Becker JT, Wesch J, Van Gorp W, McArthur JC: Cognitive performance after progression to AIDS: a longitudinal study from the Multicenter AIDS Cohort Study. Neurology 1995,45(2):267–275.PubMedCrossRef
4.
Stout JC, Salmon DP, Butters N, Taylor M, Peavy G, Heindel WC, Delis DC, Ryan L, Atkinson JH, Chandler JL, et al.: Decline in working memory associated with HIV infection. HNRC Group. Psychol Med 1995,25(6):1221–1232.PubMedCrossRef
5.
Bornstein RA, Nasrallah HA, Para MF, Whitacre CC, Rosenberger P, Fass RJ: Neuropsychological performance in symptomatic and asymptomatic HIV infection. Aids 1993,7(4):519–524.PubMedCrossRef
6.
Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, Asthana D, Fujimura RK, Lee D, van Zuilen MH, Khamis I, Shapshak P, Eisdorfer C: Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clin Epidemiol 2001, 54 Suppl 1: S35–43. 10.1016/S0895-4356(01)00445-0PubMedCrossRef
7.
Major EO, Rausch D, Marra C, Clifford D: HIV-associated dementia. Science 2000,288(5465):440–442. 10.1126/science.288.5465.439dPubMedCrossRef
8.
Bing EG, Hays RD, Jacobson LP, Chen B, Gange SJ, Kass NE, Chmiel JS, Zucconi SL: Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study. Qual Life Res 2000,9(1):55–63. 10.1023/A:1008919227665PubMedCrossRef
9.
Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000,160(8):1123–1132. 10.1001/archinte.160.8.1123PubMedCrossRef
10.
Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD: Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004,36(1):562–566.PubMedCrossRef
11.
Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A: Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. Aids 1999,13(14):1889–1897. 10.1097/00002030-199910010-00011PubMedCrossRef
12.
Starace F, Bartoli L, Aloisi MS, Antinori A, Narciso P, Ippolito G, Ravasio L, Moioli MC, Vangi D, Gennero L, Coronado OV, Giacometti A, Nappa S, Perulli ML, Montesarchio V, La Gala A, Ricci F, Cristiano L, De Marco M, Izzo C, Pezzotti P, D'Arminio Monforte A: Cognitive and affective disorders associated to HIV infection in the HAART era: findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatr Scand 2002,106(1):20–26. 10.1034/j.1600-0447.2002.02289.xPubMedCrossRef
13.
Tozzi V, Balestra P, Galgani S, Narciso P, Sampaolesi A, Antinori A, Giulianelli M, Serraino D, Ippolito G: Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J Acquir Immune Defic Syndr 2001,28(1):19–27.PubMedCrossRef
14.
Tozzi V, Balestra P, Murri R, Galgani S, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Fantoni M, Sampaolesi A, Noto P, Ippolito G, Wu AW: Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int J STD AIDS 2004,15(4):254–259. 10.1258/095646204773557794PubMedCrossRef
15.
Hays RD, Cunningham WE, Sherbourne CD, Wilson IB, Wu AW, Cleary PD, McCaffrey DF, Fleishman JA, Crystal S, Collins R, Eggan F, Shapiro MF, Bozzette SA: Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000,108(9):714–722. 10.1016/S0002-9343(00)00387-9PubMedCrossRef
16.
Lorenz KA, Shapiro MF, Asch SM, Bozzette SA, Hays RD: Associations of symptoms and health-related quality of life: findings from a national study of persons with HIV infection. Ann Intern Med 2001,134(9 Pt 2):854–860.PubMedCrossRef
17.
Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA: Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. Aids 2000,14(2):181–187. 10.1097/00002030-200001280-00014PubMedCrossRef
18.
Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, Antinori A, Giulianelli M, Tosi G, Costa M, Sampaolesi A, Fantoni M, Noto P, Ippolito G, Wu AW: Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses 2003,19(8):643–652. 10.1089/088922203322280856PubMedCrossRef
19.
Judd FK, Cockram AM, Komiti A, Mijch AM, Hoy J, Bell R: Depressive symptoms reduced in individuals with HIV/AIDS treated with highly active antiretroviral therapy: a longitudinal study. Aust N Z J Psychiatry 2000,34(6):1015–1021. 10.1046/j.1440-1614.2000.00837.xPubMedCrossRef
20.
Low-Beer S, Chan K, Wood E, Yip B, Montaner JS, O'Shaughnessy MV, Hogg RS: Health related quality of life among persons with HIV after the use of protease inhibitors. Qual Life Res 2000,9(8):941–949. 10.1023/A:1008985728271PubMedCrossRef
21.
Fumaz CR, Tuldra A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C, Clotet B: Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002,29(3):244–253.PubMedCrossRef
22.
Nieuwkerk PT, Gisolf EH, Reijers MH, Lange JM, Danner SA, Sprangers MA: Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. Aids 2001,15(15):1985–1991. 10.1097/00002030-200110190-00011PubMedCrossRef
23.
Revicki DA, Moyle G, Stellbrink HJ, Barker C: Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 1999,13(7):851–858. 10.1097/00002030-199905070-00016PubMedCrossRef
24.
Price RW, Sidtis JJ: Evaluation of the AIDS dementia complex in clinical trials. J Acquir Immune Defic Syndr 1990, 3 Suppl 2: S51–60.PubMed
25.
Robertson KRWSRWTHCD: An instrument to assess Quality of Life: Validity. Neurosciences of HIV infection: Basic and Clinical Frontiers Clinical Neuropathology: An International Journal 1993,12(Supp1):S33.
26.
Robertson KRWSRWTHCD: An instrument to assess Quality of Life: Reliability. Neurosciences of HIV infection: Basic and Clinical Frontiers Clinical Neuropathology: An International Journal 1993,12(Supp1):S33.
27.
Ferrando SJ, Rabkin JG, van Gorp W, Lin SH, McElhiney M: Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 2003,15(2):208–214.PubMedCrossRef
28.
Tsevat J, Solzan JG, Kuntz KM, Ragland J, Currier JS, Sell RL, Weinstein MC: Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. Med Care 1996,34(1):44–57. 10.1097/00005650-199601000-00004PubMedCrossRef
29.
Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW: Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000,12(3):255–266. 10.1080/09540120050042891PubMedCrossRef
30.
Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP: Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials 2001,2(1):38–45. 10.1310/R8M7-EQ0M-CNPW-39FCPubMedCrossRef
31.
Holzemer WL, Corless IB, Nokes KM, Turner JG, Brown MA, Powell-Cope GM, Inouye J, Henry SB, Nicholas PK, Portillo CJ: Predictors of self-reported adherence in persons living with HIV disease. AIDS Patient Care STDS 1999,13(3):185–197.PubMedCrossRef
32.
Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM: Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999,29(4):824–830.PubMedCrossRef
33.
Wilson TE, Barron Y, Cohen M, Richardson J, Greenblatt R, Sacks HS, Young M: Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus. Clin Infect Dis 2002,34(4):529–534. 10.1086/338397PubMedCrossRef
Metadata
Title
Better quality of life with neuropsychological improvement on HAART
Authors
Thomas D Parsons
Alyssa J Braaten
Colin D Hall
Kevin R Robertson
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2006
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-4-11

Other articles of this Issue 1/2006

Health and Quality of Life Outcomes 1/2006 Go to the issue

Research

A promising method for identifying cross-cultural differences in patient perspective: the use of Internet-based focus groups for content validation of new Patient Reported Outcome assessments

Research

Measuring the impact and distress of health problems from the individual's perspective: development of the Perceived Impact of Problem Profile (PIPP)

Research

Impact, distress and HRQoL among Malaysian men and women with a mobility impairment

Research

Measuring health-related quality of life in adolescents and young adults: Swedish normative data for the SF-36 and the HADS, and the influence of age, gender, and method of administration

Research

Validation of an English version of the Child-OIDP index, an oral health-related quality of life measure for children

Research

Development of the Well-being questionnaire short-form in Japanese: the W-BQ12